British drugmaker to buy MedImmune - baltimoresun.com: "Industry analysts had estimated MedImmune could command about $45 to $50 per share. Yesterday, they characterized the amount AstraZeneca plans to pay - reached through an intense bidding process involving multiple suitors - as a sign of desperation among pharmaceutical makers.
'There's kind of a land grab going on,' said Peter Winter, editorial director for Burrill & Co., a San Francisco merchant bank that finances biotech businesses. 'Major biotech companies are being scooped up.'"
